The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study
Open accessAbstract
In ambulatory patients with solid cancer, routine thromboprophylaxis to prevent venous thromboembolism is not recommended. Several risk prediction scores to identify cancer patients at high risk of venous thromboembolism have been proposed, but their clinical usefulness remains a matter of debate. We evaluated and directly compared the performance of the Khorana, Vienna, PROTECHT, and CONKO scores in a multinational, prospective cohort study. Patients with advanced cancer were eligible if they were due to undergo chemotherapy or had started chemotherapy in the previous three months. The primary outcome was objectively confirmed symptomatic or incidental deep vein thrombosis or pulmonary embolism during a 6-month follow-up period. A total of 876 patients were enrolled, of whom 260 (30%) had not yet received chemotherapy. Fifty-three patients (6.1%) developed venous thromboembolism. The c-statistics of the scores ranged from 0.50 to 0.57. At the conventional positivity threshold of 3 points, the scores classified 13-34% of patients as high-risk; the 6-month incidence of venous thromboembolism in these patients ranged from 6.5% (95%CI: 2.8-12) for the Khorana score to 9.6% (95%CI: 6.6-13) for the PROTECHT score. High-risk patients had a significantly increased risk of venous thromboembolism when using the Vienna (subhazard ratio 1.7; 95%CI: 1.0-3.1) or PROTECHT (subhazard ratio 2.1; 95%CI: 1.2-3.6) scores. In conclusion, the prediction scores performed poorly in predicting venous thromboembolism in cancer patients. The Vienna CATS and PROTECHT scores appear to discriminate better between low- and high-risk patients, but further improvements are needed before they can be considered for introduction into clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040296 · Cited by 23,020
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-8-200710160-00010 · Cited by 17,796
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290 · cited 2×
“To assess the difference in VTE risk between low-and high-risk patients, subdistribution hazard ratios (SHR) and 95% CIs for the dichotomized scores were estimated using the competing risks regression model of Fine and Gray.”
MethodRUBIN, D. B. (1976) · Biometrika · doi:10.1093/biomet/63.3.581 · Cited by 9,925
Review: a gentle introduction to imputation of missing values.
Donders, A. R. T., van der Heijden, G. J. M. G., Stijnen, T., & Moons, K. G. M. (2006) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2006.01.014 · Cited by 2,582
Cited by
Key, N. S., Khorana, A. A., Kuderer, N. M., Bohlke, K., Lee, A. Y. Y., Arcelus, J. I., Wong, S. L., Balaban, E. P., Flowers, C. R., Francis, C. W., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01461 · Cited by 1,504
Apixaban to Prevent Venous Thromboembolism in Patients with Cancer
Carrier, M., Abou-Nassar, K., Mallick, R., Tagalakis, V., Shivakumar, S., Schattner, A., Kuruvilla, P., Hill, D., Spadafora, S., Marquis, K., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814468 · Cited by 852
Venous thromboembolism in cancer patients: a population-based cohort study
Mulder, F. I., Horváth-Puhó, E., van Es, N., van Laarhoven, H. W. M., Pedersen, L., Moik, F., Ay, C., Büller, H. R., & Sørensen, H. T. (2021) · Blood · doi:10.1182/blood.2020007338 · Cited by 723
Self-citationFarge, D., Frere, C., Connors, J. M., Ay, C., Khorana, A. A., Munoz, A., Brenner, B., Kakkar, A., Rafii, H., Solymoss, S., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30336-5 · Cited by 651
Cancer-associated pathways and biomarkers of venous thrombosis
Hisada, Y., & Mackman, N. (2017) · Blood · doi:10.1182/blood-2017-03-743211 · Cited by 443
Metadata
- Authors
- van Es, N., Di Nisio, M., Cesarman, G., Kleinjan, A., Otten, H.-M., Mahé, I., Wilts, I. T., Twint, D. C., Porreca, E., Arrieta, O., Stépanian, A., Smit, K., De Tursi, M., Bleker, S. M., Bossuyt, P. M., Nieuwland, R., Kamphuisen, P. W., & Büller, H. R.
- Venue
- Haematologica
- Published
- 2017-05-26
- Volume
- 102
- Issue
- 9
- Pages
- 1494-1501
- ISSN
- 0390-6078 (ISSN-L)
- 1592-8721
- OpenAlex
- W2619705272
- Cited by
- 231
- References
- 5
- FWCI
- 22.63
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study. https://app.cochat.ai/papers/10.3324/haematol.2017.169060
- The paper
- van Es, N., Di Nisio, M., Cesarman, G., Kleinjan, A., Otten, H.-M., Mahé, I., Wilts, I. T., Twint, D. C., Porreca, E., Arrieta, O., Stépanian, A., Smit, K., De Tursi, M., Bleker, S. M., Bossuyt, P. M., Nieuwland, R., Kamphuisen, P. W., & Büller, H. R. (2017). Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study. Haematologica. https://doi.org/10.3324/haematol.2017.169060
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.